Amylyx Pharmaceuticals Inc (NAS:AMLX)

Q1 2025 Amylyx Pharmaceuticals Inc Earnings Call Transcript

May 8, 2025 / 12:00 PM GMT

Release Date Price: $4.58 (-5.95%)

Transcript 10-Q8-K

Key Points

Positve

Amylyx Pharmaceuticals Inc (AMLX) has achieved several meaningful milestones, including dosing the first participant in their pivotal phase 3 lucidity clinical trial for vexatide.
The company has strengthened its financial position by raising approximately $65.5 million, extending their cash runway through the end of 2026.
Positive topline data from the phase 2 Helios trial in Wolfram syndrome showed improvement or stabilization across all measured outcomes.
The company is preparing for a potential commercial launch of vexatide in 2027, pending approval.
Amylyx Pharmaceuticals Inc (AMLX) has a robust pipeline with multiple clinical trials targeting diseases with high unmet needs, including ALS and progressive supranuclear palsy.

Negative

There are no currently approved treatments for post-bariatric hypoglycemia (PBH), which vexatide aims to address, indicating a high-risk development area.
The company faces challenges in educating the medical community and patients about PBH and the potential benefits of vexatide.
The phase 3 lucidity trial for vexatide is still in early stages, with topline data not expected until the first half of 2026.
Amylyx Pharmaceuticals Inc (AMLX) has experienced a significant decrease in operating expenses, which may indicate reduced activity or cost-cutting measures.
The company is dealing with residual cash obligations related to the discontinuation of previous products, which could impact financial flexibility.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AMLX.OQ - Amylyx Pharmaceuticals Inc
Q1 2025 Amylyx Pharmaceuticals Inc Earnings Call
May 08, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
One.

Good morning. My name is Nin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amalix Pharmaceuticals first quarter earnings conference call. All participants will be in listen-only mode.

After today's presentation, there will be an opportunity to ask questions. To ask a question, please press one on your telephone keypad.

To withdraw your question, please press 2.

Please limit your questions to 1 with 1 follow up. If you have additional questions, you may rejoin the queue.

Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Lindsey Allen, Vice President

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.